Gain Therapeutics, Inc.
GANX
Nasdaq
Manufacturing
Chemicals
$1.80
▼
$0.04
(-2.17%)
Cap. Mercado: 78.39 M
Precio
$1.85
Cap. Mercado
78.39 M
Rango del Día
—
Rango de 52 Semanas
—
Volumen
—
Apertura —
Promedio 50D / 200D
—
Promedio 50D / 200D
—
Historial de Precios
Tendencias Financieras
Precio Objetivo de Analistas
5 analistas
Buy
Actual
$1.80
Objetivo
$7.60
$5.00
$8.00
$10.00
Pronóstico
P/E Futuro
-2.89
EPS Futuro
-$0.62
Ingresos Est.
0.0
Estimaciones de Ganancias
| Período | EPS Est. | Ingresos Est. | Analistas |
|---|---|---|---|
| FY2027 |
-$0.62
-$0.74 – -$0.47
|
0.0 | 3 |
| FY2026 |
-$0.61
-$0.79 – -$0.50
|
0.0 | 4 |
| Período | EPS Est. | Ingresos Est. | Analistas |
|---|---|---|---|
| 2026 Q2 |
-$0.15
-$0.18 – -$0.13
|
0.0 | 3 |
| 2026 Q1 |
-$0.14
-$0.15 – -$0.13
|
0.0 | 3 |
Sorpresas de Ganancias
Últimos 4 trimestres
| Trimestre | EPS Est. | EPS Real | Sorpresa |
|---|---|---|---|
| Q42025 | -$0.15 | -$0.11 | +24.1% |
| Q32025 | -$0.15 | -$0.15 | +2.2% |
| Q22025 | -$0.17 | -$0.19 | -11.8% |
| Q12025 | -$0.17 | -$0.16 | +4.0% |
ETFs Holding This Stock
BRSIX
BRSIX
0.06% weight
No fundamental snapshot available yet.
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | 55,180.0 | 55,180.0 | 140,108.0 | 164,994.0 |
| Net Income | -20.16 M | -20.41 M | -22.27 M | -17.59 M | -13.89 M |
| EPS (Diluted) | -0.61 | -0.89 | -1.71 | -1.48 | -1.37 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -18.71 M | -20.35 M | -22.25 M | -17.78 M | -13.83 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 10.21 M | 10.79 M | 11.52 M | 8.38 M | 7.16 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | 94,046.0 | 84,071.0 | 83,579.0 | 64,168.0 | 15,484.0 |
| Interest Expense | — | — | 494,234.0 | 375,357.0 | 0.0 |
| Income Tax | 861,118.0 | 536,815.0 | 79,275.0 | 92,976.0 | 4,008.0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 22.82 M | 12.12 M | 18.61 M | 24.10 M | 38.99 M |
| Total Liabilities | 4.25 M | 4.78 M | 6.03 M | 5.22 M | 4.17 M |
| Shareholders' Equity | 18.56 M | 7.34 M | 12.58 M | 18.88 M | 34.82 M |
| Total Debt | 400,953.0 | 438,504.0 | 567,850.0 | 603,393.0 | 694,294.0 |
| Cash & Equivalents | 20.84 M | 10.39 M | 11.79 M | 7.31 M | 36.88 M |
| Current Assets | 22.24 M | 11.60 M | 17.78 M | 21.09 M | 37.72 M |
| Current Liabilities | 3.35 M | 3.91 M | 4.95 M | 4.13 M | 2.55 M |
{"event":"ticker_viewed","properties":{"ticker":"GANX","listing_kind":"stock","pathname":"/stocks/ganx","exchange":"Nasdaq","country":"US"}}